mHealth Technology for High Blood Pressure in Bipolar Disorder
(iTAB-CV RCT Trial)
Trial Summary
What is the purpose of this trial?
This trial tests if text message reminders combined with self-checks can help people with high blood pressure and Bipolar Disorder take their medicine more regularly. The goal is to see if this method works better than just doing self-checks alone.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it seems you need to continue taking your prescribed antihypertensive and, if applicable, antidepressant medications.
What data supports the effectiveness of the treatment iTAB-CV for high blood pressure in individuals with bipolar disorder?
Research shows that a similar intervention combining psychoeducation and automated text messaging (iTAB-CV) improved medication adherence in individuals with both hypertension and bipolar disorder. Additionally, a psychosocial intervention for bipolar patients at risk of cardiovascular disease showed improvements in medication adherence and symptoms, suggesting that such approaches can be effective.12345
Is the mHealth technology for high blood pressure in bipolar disorder safe for humans?
How is the iTAB-CV treatment different from other treatments for high blood pressure in bipolar disorder?
Eligibility Criteria
This trial is for adults aged 21-80 with high blood pressure and bipolar disorder who have trouble sticking to their blood pressure medication. They must own a cell phone, have been diagnosed with hypertension at least 6 months ago, and be on antihypertensive meds for over 3 months. People can't join if they're unable or unwilling to do psychiatric interviews, are at high risk of suicide, have an upper arm circumference >50cm, or don't speak English.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants receive an automated device (eCAP) to track their use of antihypertensive medication for 1 month until completing their baseline assessment
Stage 1 Treatment
Participants are randomized to either iTAB-CV + self-monitoring or self-monitoring alone for 2 months with an interim phone/video assessment for adherence
Stage 2 Treatment
Participants in iTAB-CV are re-randomized to receive either a high intensity or low intensity booster + self-monitoring compared to self-monitoring alone
Follow-up
Participants are monitored for adherence and health outcomes without intervention
Treatment Details
Interventions
- iTAB-CV (Behavioral Intervention)
- Self-Monitoring (Behavioral Intervention)